Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.78 |
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | THPO | P40225 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyryl-Carnitine SCHEMBL886918 | 1.00 | MEN1 (0.78) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL288391 | 1.00 | MEN1 (0.78) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL28712508 | 0.98 | MEN1 (0.76) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL28900550 | 0.94 | MEN1 (0.70) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL7048157 | 0.91 | MEN1 (0.77) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL288262 | 0.90 | MEN1 (0.89) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL886920 | 0.90 | MEN1 (0.89) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Butyryl-Carnitine SCHEMBL6469306 | 0.90 | MEN1 (0.76) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL8977796 | 0.89 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL235082 | 0.89 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1058 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098860-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | SOC DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE S E C (CA) | 2026-04-09 | — | — | US | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4692783-A1 | BIOMARKER AND SYSTEM FOR PREDICTING EVOLUTION INTO ACLF OR DEATH OF ACLF PATIENT, AND USES THEREOF | Shanghai Ganning Medical and Technology Co., Ltd (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| EP-4587818-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE, S.E.C. (CA) | 2025-07-23 | — | — | EP | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-120092177-A | Sensor, kit and method for detecting biomarkers in saliva | 索科普哈应用研究产品商业化基因科学有限合伙公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119534850-A | Marker group capable of reflecting prolongation of post-PCI proinflammatory period of ACS patient and application thereof | 天津中医药大学 | 2025-02-28 | — | — | CN | claimed |
| US-20250003930-A1 | METHOD FOR ANALYZING AMINO ACIDS AND/OR ACYLCARNITINES | SHIMADZU CORPORATION (JP) | 2025-01-02 | — | — | US | claimed |
| WO-1999052517-A2 | COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-21 | — | — | WO | claimed |
| US-RE36331-E | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-05 | — | — | US | claimed |
| EP-0722724-B1 | Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants | SIGMA TAU IND FARMACEUTI (IT) | 1999-03-24 | — | — | EP | claimed |
| WO-1999006039-A1 | COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND LONG-CHAIN ALKANOLS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-02-11 | — | — | WO | claimed |
| WO-1999001126-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-01-14 | — | — | WO | claimed |
| US-5576348-A | Pharmaceutical preparation comprising an acylcarnitine | KURATSUNE HIROHIKO (JP) | 1996-11-19 | — | — | US | claimed |
| US-5496821-A | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-03-05 | — | — | US | claimed |
| EP-0681839-A2 | A pharmaceutical preparation comprising an acylcarnitine | Kuratsune, Hirohiko (JP) | 1995-11-15 | — | — | EP | claimed |
| US-4415589-A | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1983-11-15 | — | — | US | claimed |
| US-4194006-A | ANTIARRHYTHMIA | CAVAZZA CLAUDIO (IT) | 1980-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | MEN1 361/4885KMT2A 2945/4885MAPT 132/4885 |
| US-20260098860-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | MB, TAS2R40, MUC1 | MEN1 1646/4885KMT2A 581/4885MAPT 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.